J Korean Diabetes.  2017 Sep;18(3):135-140. 10.4093/jkd.2017.18.3.135.

Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice

• Kim NH
• Kim SG

• KMID: 2390865
• DOI: http://doi.org/10.4093/jkd.2017.18.3.135

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are newer classes of glucose-lowering agents that are currently widely used in clinical practice. Their glycemic efficacy and cardiovascular safety have been well proven, and recent large clinical trials even have shown cardiovascular benefits of SGLT2 inhibitors. However, data regarding drug-related long-term safety remain inconclusive. Recently, several safety issues related to DPP-4 inhibitors and SGLT2 inhibitors have been raised by cardiovascular outcome trials or post-marketing pharmacoepidemiological studies. In this review, we summarize emerging safety issues regarding the use of DPP-4 inhibitors and SGLT2 inhibitors in type 2 diabetes and suggest how to interpret and apply these results to clinical practice.

Keyword

Diabetes mellitus; type 2; Dipeptidyl-peptidase IV inhibitors; Safety; Sodium glucose cotransporter 2 inhibitor

MeSH Terms

Diabetes Mellitus
Dipeptidyl-Peptidase IV Inhibitors
Glucose*
Sodium*
Dipeptidyl-Peptidase IV Inhibitors
Glucose
Sodium

Reference

1. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995; 273:1605–1609.

2. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009; 32:834–838.

3. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141:150–156.

4. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013; 62:2595–2604.

5. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369:1317–1326.

6. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369:1327–1335.

7. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373:232–242.

8. Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2017; 40:284–286.

9. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003; 56:164–170.

10. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P. Canadian Network for Observational Drug Effect Studies Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016; 352:i581.

11. Lee CS, Kim YG, Cho HJ, Park J, Jeong H, Lee SE, Lee SP, Kang HJ, Kim HS. Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation. Sci Rep. 2016; 6:29393.

12. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375:323–334.

13. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; [Epub ahead of print]. DOI: 10.1056/NEJMoa1611925.

14. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016; 39:Suppl 2. S165–S171.

15. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017; 376:2300–2302.

16. Jabbour SA, Seufert J, Scheen AJ, Bailey CJ, Karup C, Langkilde AM. Safety update on dapagliflozin (DAPA) across the phase 2b/3 clinical trial program. In : American Diabetes Association 77th Scientific Sessions; 2017 Jun 9-13; San Diego, USA. Abstract (No. 2017-A-4681-Diabetes).

17. Korean Society of Pharmacoepidemiology and Risk Management. Pharmacoepidemiology. Seoul: Seoul National University Press;2011.

18. Shi L, Zhao Y, Szymanski K, Yau L, Fonseca V. Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. J Diabetes Complications. 2011; 25:143–150.